Addition of an induction regimen of antiangiogenesis and antitumor immunity to standard chemotherapy improves survival in advanced malignancies

Medical Oncology

Volumn 29, Issue 5, 2012, Pages 3626-3633

  Lasalvia Prisco, Eduardo ^a,b,c   Goldschmidt, Pablo ^e   Galmarini, Felipe ^f   Cucchi, Silvia ^a   Vázquez, Jesús ^a   Aghazarian, Martha ^a,d   Lasalvia Galante, Eduardo ^a,d   Golomar, Wilson ^a,d   Gordon, William ^g  

^a Interdoctors Network   (Uruguay)

^b UNIVERSIDAD DE LA REPÚBLICA   (Uruguay)

^c (F) National Cancer Institute   (Uruguay)

^d National Cancer Institute   (Uruguay)

^e Interdoctors Network   (France)

^f Interdoctors Network   (Argentina)

^g Interdoctors Network   (United States)

Author keywords

Antiangiogenesis; Antitumor immunity; Chemotherapy; Immune tolerance; Immunotherapy; Neoangiogenesis

Indexed keywords

ACETYLCYSTEINE; CARBOPLATIN; CELECOXIB; CISPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; GEMCITABINE; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; PYRAZOLE DERIVATIVE; SULFONAMIDE; TUMOR ANTIGEN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER PROGNOSIS; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; HUMAN; INDUCTION CHEMOTHERAPY; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; MALE; OUTCOME ASSESSMENT; PANCREAS CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE CANCER; RANDOMIZED CONTROLLED TRIAL; SURVIVAL TIME; CARCINOMA; CONTROLLED CLINICAL TRIAL; IMMUNIZATION; IMMUNOLOGY; IMMUNOTHERAPY; KAPLAN MEIER METHOD; METHODOLOGY; MORTALITY; PANCREAS TUMOR; PROSTATE TUMOR;

ACETYLCYSTEINE; ANGIOGENESIS INHIBITORS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; CARCINOMA; CARCINOMA, NON-SMALL-CELL LUNG; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; IMMUNIZATION; IMMUNOTHERAPY; INDUCTION CHEMOTHERAPY; KAPLAN-MEIER ESTIMATE; MALE; PANCREATIC NEOPLASMS; PROSTATIC NEOPLASMS; PYRAZOLES; SULFONAMIDES;

EID: 84880269240     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-012-0301-1     Document Type: Article

References (36)

1. Zitvogel L, Apetoh L, Ghiringhelli F, et al. The anticancer immune response: indispensable for therapeutic success? J Clin Invest. 2008;118:1991-2001.
2. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-6.
3. Mulcahy MF. Bevacizumab in the therapy for refractory metastatic colorectal cancer. Biologics. 2008;2(1):53-9.
4. Lasalvia-Prisco E, Goldschmidt P, Galmarini F, et al. Switch of biological response (angiogenesis and immunity) as target of complementary treatments in malignancy. In: 37th ESMO congress, Vienna 2012, 28 Sept-02 Oct 2012. Accepted.
5. Miller K, Sweeney CJ, Sledge GW Jr. Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol. 2001;19:1195-206.
6. Correale P, Del Vecchio MT, La Placa M, et al. chemotherapeutic drugs may be used to enhance the killing efficacy of human tumor antigen peptide-specific CTLs. J Immunother. 2008;31:132-47.
7. Masferrer JL, Koki A, Seibert K. COX-2 inhibitors a new class of antiangiogenic agents. Ann N Y Acad Sci. 1999;889:84-6.
8. Soff GA, Wang H, Cundiff DL, et al. In vivo generation of angiostatin isoforms by administration of a plasminogen activator and a free sulphydryl donor: a phase I study of an angiostatic cocktail of tissue plasminogen activator and mesna. Clin Cancer Res. 2005;11(17):6218-25.
9. Lasalvia-Prisco E, Garcia-Giralt E, Vázquez J, et al. Randomized phase II clinical trial of chemo-immunotherapy in advanced non-small cell lung cancer. Biol Targets Ther. 2008;2(3):555-61.
10. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) Research Data (1973-2009), National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2012, based Nov 2011.
11. World Medical Association. 2004. Declaration of Helsinki, URL http://www.wma.net.
12. Oken MM, Creech RH, Tormey DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982;5:649-55.
13. Lasalvia-Prisco E, Cucchi S, Vázquez J, et al. Antitumoral effect of a vaccination procedure with an autologous hemoderivative. Cancer Biol Ther. 2003;2(2):155-60.
14. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol. 2003;13:176-81.
15. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. Natl Cancer Inst. 1993;85:365-76.
16. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-81.
17. Zou W. Immunosuppressive networks in the tumor environment and their therapeutic relevance. Nat Rev. 2005;5:263-74.
18. Liyanage UK, Moore TT, Joo HG, et al. Prevalence of regulatory T cells is increased in peripheral blood and tumor microenvironment of patients with pancreas or breast adenocarcinoma. J Immunol. 2002;169:2756-61.
19. Pinzon-Charry A, Ho CSK, Maxwell T, et al. Numerical and functional defects of blood dendritic cells in early- and late-stage breast cancer. Br J Cancer. 2007;97:1251-9.
20. Lissoni P, Brivio F, Fumagalli L, et al. Effects of the conventional antitumor therapies surgery, chemotherapy, radiotherapy and immunotherapy on regulatory T lymphocytes in cancer patients. Anticancer Res. 2009;29(5):1847-52.
21. Ghiringhelli F, Menard C, Puig PE, et al. Metronomic cyclophosphamide regimen selectively depletes CD4+ CD25+ regulatory T cells and restores T and NK effector functions in end stage cancer patients. Cancer Immunol Immunother. 2007;56:641-8.
22. Lee SY, Choi HK, Lee KJ, et al. The immune tolerance of cancer is mediated by IDO that is inhibited by COX-2 inhibitors through regulatory T cells. J Immunother. 2009;32:22-8.
23. Talarn C, Urbano-Ispizua A, Martino R, et al. G-CSF increases the number of peripheral blood dendritic cells CD16+ and modifies the expression of the costimulatory molecule CD86+. Bone Marrow Transplant. 2006;37:873-9.
24. Gately S, Twardowski P, Stack MS, et al. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc Natl Acad Sci USA. 1997;94:10868-72.
25. Griffioen AW. Anti-angiogenesis: making the tumor vulnerable to the immune system. Symposium Paper. Cancer Immunol Immunother. 2008;57:1553-8.
26. Lomakin MS, Larin AS, Maiskii IN. Thermostable antigens of malignant tumors and normal tissues of experimental animals. Biull Eksp Biol Med. 1978;85(6):726-728 (Russia).
27. Lomakin MS, Larin AS, Maiskii IN. Thermo-stable tumor-associated antigens in the serum of tumor-bearing animals and in tissue cultures of malignant tumors. Biull Eksp Biol Med. 1980 Apr;89(4):452-454 (Russia).
28. Goufman EI, Moshkovskii SA, Tikhonova OV, et al. Two-dimensional electrophoretic proteome study of serum thermostable fraction from patients with various tumor conditions. Biochem Biokhimiia. 2006;71(4):354-60 (Russia).
29. Frelinger JA, Robinson BWS, Scott B, et al. Tumor-specific CD8 T cells cross-priming rather than cross-tolerizing host increases tumor antigen cross-presentation. J Immunol. 2003;170:4905-13.
30. Fridlender ZG, Sun J, Singhal S, et al. Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms. Mol Ther. 2010;18(11):1947-59.
31. Melcher A, Todryk S, Hardwick N, et al. Tumor Immunogenicity is determined by the mechanism of cell death via induction of heat shock protein induction. Nat Med. 1998;4(5):581-7.
32. Belli F, Testori A, Rivoltini L, et al. Vaccination of metastatic melanoma patients with autologous tumor derived heat shock protein gp96-peptide complexes: clinical and immunologic findings. J Clin Oncol. 2002;20(20):4169-80.
33. Mazzaferro V, Coppa J, Carrabba MG, et al. Vaccination with autologous tumor-derived heat-shock protein gp96 after liver resection for metastatic colorectal cancer. Clin Cancer Res. 2003;9(9):3235-45.
34. Maki RG, Livingston PO, Lewis JJ, et al. A phase I pilot study of autologous heat shock protein vaccine HSPPC-96 in patients with resected pancreatic adenocarcinoma. Dig Dis Sci. 2007;52(8):1964-72.
35. Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Mini-review. Cell Stress Chaperones. 2005;10(2):86-103.
36. Emens LA, MD. PhD. A new twist on autologous cancer vaccines. Cancer Biol Ther. Mar/Apr 2003;2(2):161-163 (commentary).